Metformin in the treatment of non-alcoholic fatty liver disease: safety, efficacy and mechanism
Metformin in the treatment of non-alcoholic fatty liver disease: safety, efficacy and mechanism
复制标题
DOI：
10.1586/17474124.2014.894880
复制
发表时间：
2014-05-01
影响因子：
3.9
通讯作者：
Abenavoli, Ludovico
中科院分区：
文献类型：
--
作者：
Rouabhia, Samir;Milic, Natasa;Abenavoli, Ludovico
Non-alcoholic fatty liver disease (NAFLD) is the most common liver disease etiology worldwide. It encompasses a spectrum ranging from simple steatosis to non-alcoholic steatohepatitis. Although the physiopathology of NAFLD is partly known. Insulin-resistance plays a central role in the development and progression of NAFLD. Several studies have indicated that metformin, as an insulin sensitizer, effectively improves NAFLD and its related metabolic status. Metformin was effective in reducing enzyme levels in the short period, but very limited and controversial information are available on liver histology. Larger randomized controlled trials of sufficient duration using clearly defined histological endpoints are needed to fully assess the efficacy of this drug in modifying the natural history of NAFLD.
